Genprex, Inc. is set to present remarkable preclinical data on GPX-002, a groundbreaking gene therapy for diabetes, during the ASGCT Annual Meeting in New Orleans.

Genprex (NASDAQ: GNPX) has signed a new Sponsored Research Agreement (SRA) with the University of Pittsburgh to study GPX-002, its gene therapy treatment for Type 1 (T1D) and Type 2 diabetes (T2D) in animal models. Previous preclinical data showed statistically significant improvements in insulin requirements, c-peptide levels, and glucose tolerance. GPX-002 uses an AAV vector containing Pdx1 and MafA genes administered into the pancreatic duct. In T1D, it transforms alpha cells into functional beta-like cells that produce insulin while potentially evading immune response. For T2D, the therapy aims to rejuvenate exhausted beta cells. The treatment can be administered in humans through routine endoscopy.

Reported Thursday, May 14 - 8:07am EDT (TheFly subscription required to read more.)

Reported Tuesday, Jan 6 - 7:04am EST (TheFly subscription required to read more.)

Reported Tuesday, Jun 24 - 9:27am EDT (TheFly subscription required to read more.)

Reported Monday, Jun 23 - 9:07am EDT (TheFly subscription required to read more.)

Reported Wednesday, May 28 - 7:07am EDT (TheFly subscription required to read more.)

Genprex, Inc. has announced major advancements in its diabetes gene therapy program, particularly with GPX-002, to treat Type 1 and Type 2 diabetes. Discover their latest developments.

Genprex, Inc. revealed significant preliminary findings for GPX-002, a revolutionary gene therapy addressing Type 2 diabetes, featuring animal study advancements.

Genprex presents its promising diabetes gene therapy research at the ADA 85th Scientific Sessions, focusing on revolutionary treatments for diabetes.

Genprex's promising diabetes gene therapy GPX-002 showcases positive preclinical data at the ASGCT 28th Annual Meeting, sparking hope for diabetes patients.

Genprex (NASDAQ: GNPX) provided a clinical update for its diabetes gene therapy program for GPX-002 on January 7, 2026, reporting preclinical progress and regulatory planning.Key developments: preclinical proof-of-concept in Type 2 diabetes mouse and non-human primate models showing beta cell rejuvenation and normalized glucose; prior T1D models showed restored normal glucose and improved c-peptide/insulin metrics; manufacturing process transferred to CDMO partners; and a FDA meeting request submitted by end of 2025, with the meeting scheduled in Q1 2026 to discuss IND-enabling studies and next steps toward toxicology studies and cGMP clinical scale production.

Genprex (NASDAQ: GNPX) announced preliminary preclinical in vivo proof-of-concept data for GPX-002, a diabetes gene therapy, from Type 2 diabetic non-human primate (NHP) and mouse studies dated Jan 6, 2026. Key findings: one NHP treated via pancreatic duct infusion achieved normal glucose tolerance at seven months; a second NHP treated by direct pancreatic injection improved glucose tolerance at three months but did not normalize; T2D mice showed statistically significant glucose tolerance improvement at four weeks and restoration of normal glucose levels. Studies used an AAV vector carrying Pdx1 and MafA with an insulin promoter. Ongoing work includes toxicology and IND planning.

Genprex (NASDAQ: GNPX) presented positive preclinical research results for GPX-002, its diabetes gene therapy drug candidate, at the 2025 American Diabetes Association Scientific Sessions. The therapy demonstrated promising results in non-human primates (NHPs) with streptozotocin-induced diabetes.The research showed that GPX-002, which uses recombinant adeno-associated virus (rAAV) to deliver Pdx1 and MafA genes, successfully converted alpha cells into insulin-secreting beta-like cells. The treated NHPs showed improved glucose tolerance and reduced insulin requirements one month post-infusion. Temporary immunosuppression for 3 months proved effective in preventing anti-viral immunity, with researchers now evaluating a 6-month immunosuppression period.

New gene therapy GPX-002 demonstrates improved glucose tolerance in diabetes models. See groundbreaking preclinical data presented at ASGCT conference. Get Details

Genprex (NASDAQ: GNPX) announced advancement in its diabetes program through a strategic collaboration with a CDMO partner to research a non-viral lipid nanoparticle delivery system for its diabetes gene therapy drug candidate. This alternative approach represents a second-generation development, separate from existing preclinical programs.The company's current diabetes treatment, GPX-002, uses an AAV vector containing Pdx1 and MafA genes administered into the pancreatic duct. While effective, viral delivery systems cannot be readministered due to immune responses. The non-viral approach could enable multiple treatments, potentially optimizing patient outcomes.Recent preclinical studies showed GPX-002's effectiveness in Type 1 NOD mouse models, maintaining glucose control for approximately 120 days, significantly longer than the 17-day median observed with traditional islet cell transplants. The therapy is being developed for both Type 1 and Type 2 diabetes, working by transforming pancreatic alpha cells into functional beta-like cells.

Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy in Type 2 Diabetic Non-Human Primates GPX-002 Rejuvenated Exhausted Beta Cells and Normalized Glucose Levels in Type 2 Diabetic Mice AUSTIN, Texas, Jan. 6, 2026 /PRNewswire/ -- Genprex, Inc....